Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
PBAX Stock Summary
In the News
PBAX Financial details
Company Rating
Sell
Market Cap
36.47M
Income
-2.41M
Revenue
254.83K
Book val./share
-0.87
Cash/share
1.33
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
-29.04
Forward P/E
-
PEG
-0.13
P/S
270.6
P/B
-12.76
P/C
4.4
P/FCF
-40.32
Quick Ratio
0.02
Current Ratio
1.76
Debt / Equity
-0.25
LT Debt / Equity
-
-
-
EPS (TTM)
-0.33
EPS next Y
-
EPS next Q
1.58
EPS this Y
172.26%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-74.9%
-
-
-
-
SMA20
-32.61%
SMA50
-31.25%
SMA100
-
Inst Own
9.97%
Inst Trans
0.6%
ROA
-28%
ROE
2027%
ROC
-0.36%
Gross Margin
100%
Oper. Margin
-520%
Profit Margin
-945%
Payout
-
Shs Outstand
6.23M
Shs Float
940.12K
-
-
-
-
Target Price
-
52W Range
4.12-12.8
52W High
-51.25%
52W Low
+46.25%
RSI
29.6
Rel Volume
0.76
Avg Volume
8.08K
Volume
6.12K
Perf Week
-40.37%
Perf Month
-46.82%
Perf Quarter
-
Perf Half Y
-46.48%
-
-
-
-
Beta
0.044
-
-
Volatility
1.9%, 2.1%
Prev Close
4.65%
Price
5.85
Change
16.77%
PBAX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2021-12-31 | 2022-12-31 |
---|---|---|---|
2.02K | 2.02K | ||
Revenue per share | 0 | 0.01 | |
Net income per share | -0.01 | -0.04 | |
Operating cash flow per share | -0.03 | -0.06 | |
Free cash flow per share | -0.03 | -0.06 | |
Cash per share | 0.05 | 0.03 | |
Book value per share | 7.43 | 0.14 | |
Tangible book value per share | 7.43 | 0.14 | |
Share holders equity per share | 7.43 | 0.14 | |
Interest debt per share | 0 | 0.04 | |
Market cap | 227.74M | 183.8M | |
Enterprise value | 226.65M | 183.97M | |
P/E ratio | -721.74 | -275.25 | |
Price to sales ratio | 0 | 721.25 | |
POCF ratio | -326.7 | -168.27 | |
PFCF ratio | -326.7 | -168.27 | |
P/B Ratio | 1.33 | 74.45 | |
PTB ratio | 1.33 | 74.45 | |
EV to sales | 0 | 721.93 | |
Enterprise value over EBITDA | -682.61 | -32.04 | |
EV to operating cash flow | -325.12 | -168.43 | |
EV to free cash flow | -325.12 | -168.43 | |
Earnings yield | 0 | 0 | |
Free cash flow yield | 0 | -0.01 | |
Debt to equity | 0 | 0.26 | |
Debt to assets | 0 | 0.02 | |
Net debt to EBITDA | 3.31 | -0.03 | |
Current ratio | 13.88 | 1.38 | |
Interest coverage | 0 | 0 | |
Income quality | 2.21 | 1.64 | |
Dividend Yield | 0 | 0 | |
Payout ratio | 0 | 0 | |
Sales general and administrative to revenue | 0 | 11.15 | |
Research and developement to revenue | 0 | 0 | |
Intangibles to total assets | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | |
Capex to revenue | 0 | 0 | |
Capex to depreciation | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | |
Graham number | 1.52 | 0.34 | |
ROIC | 0 | -0.21 | |
Return on tangible assets | 0 | -0.02 | |
Graham Net | -0.35 | -2.2 | |
Working capital | 1.26M | 11.62M | |
Tangible asset value | 170.83M | 2.47M | |
Net current asset value | -7.89M | 2.47M | |
Invested capital | 0 | 0.26 | |
Average receivables | 0 | 0 | |
Average payables | 0 | 833.78K | |
Average inventory | 0 | 0 | |
Days sales outstanding | 0 | 0 | |
Days payables outstanding | 0 | 0 | |
Days of inventory on hand | 0 | 0 | |
Receivables turnover | 0 | 0 | |
Payables turnover | 0 | 0 | |
Inventory turnover | 0 | 0 | |
ROE | 0 | -0.27 | |
Capex per share | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0.01 | 0 | 0 | 0 | |
Net income per share | 0 | -0.01 | -0.06 | -0.21 | -0.05 | |
Operating cash flow per share | -0.01 | -0.02 | -0.03 | -0.13 | -0.04 | |
Free cash flow per share | -0.01 | -0.02 | -0.03 | -0.13 | -0.04 | |
Cash per share | 7.84 | 0.02 | 2.1 | 2.07 | 1.33 | |
Book value per share | 7.42 | 0.11 | 0.29 | 0.08 | -0.87 | |
Tangible book value per share | 7.42 | 0.11 | 0.29 | 0.08 | -0.87 | |
Share holders equity per share | 7.42 | 0.11 | 0.29 | 0.08 | -0.87 | |
Interest debt per share | 0 | 0.03 | 0.08 | 0.17 | 0.22 | |
Market cap | 231.88M | 236.02M | 72.3M | 73.79M | 68.77M | |
Enterprise value | 231.37M | 236.19M | 72.77M | 74.86M | 70.05M | |
P/E ratio | 686 | -224.63 | -48.44 | -12.83 | -51.47 | |
Price to sales ratio | 0 | 926.17 | 0 | 0 | 0 | |
POCF ratio | -1.33K | -632.58 | -365.56 | -83.56 | -268.51 | |
PFCF ratio | -1.33K | -632.58 | -365.56 | -83.56 | -268.51 | |
P/B Ratio | 1.36 | 95.6 | 36.39 | 134.34 | -12.55 | |
PTB ratio | 1.36 | 95.6 | 36.39 | 134.34 | -12.55 | |
EV to sales | 0 | 926.86 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -154.47 | -73.62 | -123.28 | -48.5 | -162.97 | |
EV to operating cash flow | -1.33K | -633.05 | -367.94 | -84.77 | -273.49 | |
EV to free cash flow | -1.33K | -633.05 | -367.94 | -84.77 | -273.49 | |
Earnings yield | 0 | 0 | -0.01 | -0.02 | 0 | |
Free cash flow yield | 0 | 0 | 0 | -0.01 | 0 | |
Debt to equity | 0 | 0.26 | 0.33 | 2.14 | -0.25 | |
Debt to assets | 0 | 0.02 | 0.05 | 0.08 | 0.16 | |
Net debt to EBITDA | 0.34 | -0.05 | -0.8 | -0.69 | -2.97 | |
Current ratio | 0.9 | 1.38 | 4.38 | 3.2 | 1.76 | |
Interest coverage | 0 | 3.71 | 5.44 | 0 | 0 | |
Income quality | -2.06 | 1.42 | 0.41 | 0.61 | 0.77 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 5.39 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0.78 | 0.17 | 0.6 | 0.62 | 1.01 | |
ROIC | 0 | -0.12 | -0.17 | -0.92 | -0.11 | |
Return on tangible assets | 0 | -0.01 | -0.03 | -0.1 | -0.04 | |
Graham Net | 7.4 | -1.72 | 0.26 | 0.07 | -0.87 | |
Working capital | -90.68K | 11.62M | 11.14M | 9.7M | 3.67M | |
Tangible asset value | 170.43M | 2.47M | 1.99M | 549.25K | -5.48M | |
Net current asset value | -9.24M | 2.47M | 1.99M | 549.25K | -5.48M | |
Invested capital | 0 | 0.26 | 0.33 | 2.14 | -0.25 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 436.68K | 1.18M | 1.84M | 2.58M | 3.23M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0 | -0.11 | -0.19 | -2.62 | 0.06 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
PBAX Frequently Asked Questions
What is Phoenix Biotech Acquisition Corp. stock symbol ?
Phoenix Biotech Acquisition Corp. is a US stock , located in Oakland of Ca and trading under the symbol PBAX
What is Phoenix Biotech Acquisition Corp. stock quote today ?
Phoenix Biotech Acquisition Corp. stock price is $5.85 today.
Is Phoenix Biotech Acquisition Corp. stock public?
Yes, Phoenix Biotech Acquisition Corp. is a publicly traded company.